NGM·Healthcare·$74M·#256 / 520 in Healthcare
TCRX TScan Therapeutics, Inc.
43SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY0
STABILITY41
VALUATION59
GOVERNANCE34
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+266.7%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
14 months
46
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
76.5%
31
< 25% strong
Price / Sales
Market cap relative to trailing revenue
7.2x
59
< 3x strong
Rule of 40
Growth rate plus operating margin
-1049
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.2%
2
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-1.4%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE TCRX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when TCRX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.